TABLE 1.
Clinical manifestations of patients with non‐small‐cell lung cancer (NSCLC)
| Characteristic | Total (n = 24) | NR (n = 12) | R (n = 12) | P value |
|---|---|---|---|---|
| Age, y | ||||
| Median | 61.64 | 60.67 | 62.33 | >.05 |
| Sex | ||||
| Male | 21 | 9 (75.00) | 12 (100.00) | .064 |
| Female | 3 | 3 (25.00) | 0 (0.00) | .217 |
| History | ||||
| Squamous | 12 | 6 (50.00) | 6 (50.00) | >.05 |
| Nonsquamous | 12 | 6 (50.00) | 6 (50.00) | >.05 |
| Smoking status | ||||
| Smoker | 17 | 6 (50.00) | 11 (91.67) | .025 |
| Nonsmoker | 7 | 6 (50.00) | 1 (8.33) | .069 |
| Disease stage | ||||
| III | 4 | 3 (25.00) | 1 (8.33) | .273 |
| IV | 20 | 9 (75.00) | 11 (91.67) | .590 |
| EGFR mutation | ||||
| Yes | 3 | 1 (8.33) | 2 (16.67) | .534 |
| No | 19 | 10 (83.33) | 9 (75.00) | 1.000 |
| ALK mutation | ||||
| Yes | 0 | 0 (0.00) | 0 (0.00) | |
| No | 20 | 11 (91.67) | 9 (75.00) | |
| T stage | ||||
| 1 | 3 | 2 | 1 | .068 |
| 2 | 8 | 5 | 3 | .081 |
| 3 | 5 | 4 | 1 | |
| 4 | 8 | 1 | 7 | |
| N stage | ||||
| 0 | 4 | 3 | 1 | .392 |
| 1 | 1 | 1 | 0 | .413 |
| 2 | 10 | 5 | 5 | |
| 3 | 9 | 3 | 6 | |
| M stage | ||||
| 0 | 4 | 3 | 1 | .273 |
| 1 | 20 | 9 | 11 | .590 |
Formalin‐embedded sections from 24 patients with advanced NSCLC were subjected to multiplex immunofluorescence assay to determine the infiltrating lymphocyte profiles. Patients were subgrouped into nonresponder (NR; n = 12) and responder (R; n = 12) groups according to disease progression at 8 wk after treatment and were followed up until the end of the treatment for calculating progression‐free survival values. Bold value shows the significant difference (P = .025 < .05).